{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T01:03:22Z","timestamp":1776733402675,"version":"3.51.2"},"reference-count":86,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1053\/j.gastro.2017.03.018","type":"journal-article","created":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T16:32:16Z","timestamp":1490286736000},"page":"1578-1587","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["American Gastroenterological Association Institute Clinical Practice Update\u2014Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection"],"prefix":"10.1053","volume":"152","author":[{"given":"Ira M.","family":"Jacobson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph K.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"Fried","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2017.03.018_bib1","first-page":"290","article-title":"The new era of interferon-free treatment of chronic hepatitis C","volume":"31","author":"Solbach","year":"2015","journal-title":"Viszeralmedizin"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2017.03.018_bib2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/liv.13027","article-title":"Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives","volume":"36","author":"Asselah","year":"2016","journal-title":"Liver Int"},{"key":"10.1053\/j.gastro.2017.03.018_bib3","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.gtc.2015.07.009","article-title":"Hepatitis C virus: current and evolving treatments for genotypes 2 and 3","volume":"44","author":"Ampuero","year":"2015","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1053\/j.gastro.2017.03.018_bib4","doi-asserted-by":"crossref","unstructured":"Asselah T, Bourliere M. Hepatitis C virus: current and evolving treatments for genotype Gastroenterol Clin North Am 2015;44:859\u2212870.","DOI":"10.1016\/j.gtc.2015.07.013"},{"key":"10.1053\/j.gastro.2017.03.018_bib5","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.gtc.2015.07.010","article-title":"Current treatment options in patients with hepatitis C Virus Genotype 6","volume":"44","author":"Nguyen","year":"2015","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1053\/j.gastro.2017.03.018_bib6","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.gtc.2015.06.001","article-title":"Current and evolving treatments of genotype 1 hepatitis C virus","volume":"44","author":"Alqahtani","year":"2015","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1053\/j.gastro.2017.03.018_bib7","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/cid\/cir076","article-title":"Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more","volume":"52","author":"Pearlman","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.gastro.2017.03.018_bib8","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2010.07.009","article-title":"A\u00a0sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin","volume":"139","author":"Swain","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2017.03.018_bib9","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/jvh.12074","article-title":"Long-term clearance of hepatitis C virus following interferon alpha-2b or peginterferon alpha-2b, alone or in combination with ribavirin","volume":"20","author":"Manns","year":"2013","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1053\/j.gastro.2017.03.018_bib10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hep.27366","article-title":"Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus","volume":"61","author":"Yoshida","year":"2015","journal-title":"Hepatology"},{"issue":"Suppl","key":"10.1053\/j.gastro.2017.03.018_bib11","doi-asserted-by":"crossref","first-page":"S449","DOI":"10.1016\/S0168-8278(14)61272-1","article-title":"Long term follow-up of\u00a0patients treated with sofosbuvir in the FISSION, POSITRON, FUSION and NEUTRINO phase 3 studies","volume":"60","author":"Cheng","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2017.03.018_bib12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/cid\/ciw676","article-title":"Late relapse versus HCV reinfection in patients with sustained virologic response after sofosbuvir-based therapies","volume":"64","author":"Sarrazin","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"Suppl","key":"10.1053\/j.gastro.2017.03.018_bib13","first-page":"743A","article-title":"Long-term efficacy of ombitasvir\/paritaprevir\/r and Dasabuvir with or without ribavirin in HCV genotype 1-infected patients with or without cirrhosis","volume":"62","author":"Zeuzem","year":"2015","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2017.03.018_bib14","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.cgh.2011.03.004","article-title":"A\u00a0sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C","volume":"9","author":"Backus","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2017.03.018_bib15","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jhep.2009.12.028","article-title":"Ipact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis","volume":"52","author":"Cardoso","year":"2010","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2017.03.018_bib16","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2017.03.018_bib17","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.gastro.2016.09.009","article-title":"Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications","volume":"152","author":"Nahon","year":"2017","journal-title":"Gastrenterology"},{"key":"10.1053\/j.gastro.2017.03.018_bib18","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.22694","article-title":"Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients","volume":"49","author":"George","year":"2009","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2017.03.018_bib19","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/hepr.12331","article-title":"Progressive fibrosis significantly correlates with hepatocellular carcinoma in patients with a sustained virological response","volume":"45","author":"Tachi","year":"2015","journal-title":"Hepatol Res"},{"key":"10.1053\/j.gastro.2017.03.018_bib20","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.25606","article-title":"A\u00a0morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis","volume":"56","author":"D'Ambrosio","year":"2012","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2017.03.018_bib21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.antiviral.2014.03.012","article-title":"Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C?","volume":"107","author":"Lee","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1053\/j.gastro.2017.03.018_bib22","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2013.02.039","article-title":"Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies","volume":"144","author":"Chen","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2017.03.018_bib23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/CLEP.S53302","article-title":"SVR12 is higher than SVR24 in treatment-na\u00efve hepatitis C genotype 1 patients treated with peginterferon plus ribavirin","volume":"6","author":"Thorlund","year":"2014","journal-title":"Clin Epidemiol"},{"key":"10.1053\/j.gastro.2017.03.018_bib24","article-title":"Concordance between SVR-4, SVR-12 and SVR-24 in genotype 1 HCV infected patients who received all oral fixed dose combination ledipasvir\/sofosbuvir with or without ribavirin in phase 3 clinical trials","volume":"60","author":"Bernstein","year":"2014","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2017.03.018_bib25","unstructured":"American Association for the Study of the Liver-Infectious Diseases of America. HCV guidance: recommendations for testing, management, and treating hepatitis C 2016. Available at www.hcvguidelines.org. Accessed July 6,\u00a02016."},{"key":"10.1053\/j.gastro.2017.03.018_bib26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL recommendations on treatment of hepatitis C 2015","volume":"63","author":"Pawlotsky","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2017.03.018_bib27","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1086\/432917","article-title":"Reemergence of hepatitis C virus after 8.5 years in a patient with hypogammaglobulinemia: evidence for an occult viral reservoir","volume":"192","author":"Lee","year":"2005","journal-title":"J\u00a0Infect Dis"},{"key":"10.1053\/j.gastro.2017.03.018_bib28","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/apt.12273","article-title":"Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy","volume":"37","author":"Koh","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2017.03.018_bib29","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/hep.21176","article-title":"The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients","volume":"43","author":"Sangiovanni","year":"2006","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2017.03.018_bib30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000337293","article-title":"A\u00a0critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: a novel approach by using meta-regression","volume":"82","author":"Shen","year":"2012","journal-title":"Oncology"},{"issue":"5 Pt 1","key":"10.1053\/j.gastro.2017.03.018_bib31","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","article-title":"Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies","volume":"158","author":"Morgan","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2017.03.018_bib32","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1007\/s00535-013-0921-z","article-title":"Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes","volume":"49","author":"Yamashita","year":"2014","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1053\/j.gastro.2017.03.018_bib33","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/jgh.13236","article-title":"Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: a large-scale, long-term cohort study","volume":"31","author":"Nagaoki","year":"2016","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2017.03.018_bib34","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hep.28535","article-title":"Risk of hepatocellular carcinoma after sustained virological response in veterans with hepatitis C virus infection","volume":"64","author":"El-Serag","year":"2016","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2017.03.018_bib35","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.gastro.2015.12.041","article-title":"Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma","volume":"150","author":"Bruix","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2017.03.018_bib36","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2017.03.018_bib37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-3-642-16037-0_3","article-title":"Imaging of hepatocellular carcinoma: current concepts","volume":"190","author":"Parikh","year":"2013","journal-title":"Recent Results Cancer Res"},{"key":"10.1053\/j.gastro.2017.03.018_bib38","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3390\/diagnostics5040513","article-title":"Imaging of HCC-current state of the art","volume":"5","author":"Schraml","year":"2015","journal-title":"Diagnostics (Basel)"},{"key":"10.1053\/j.gastro.2017.03.018_bib39","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.gastro.2008.09.014","article-title":"Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease","volume":"136","author":"Lok","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2017.03.018_bib40","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.23744","article-title":"Outcome of sustained virological responders with histologically advanced chronic hepatitis C","volume":"52","author":"Morgan","year":"2010","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2017.03.018_bib41","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00535-004-1519-2","article-title":"Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon","volume":"40","author":"Ikeda","year":"2005","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1053\/j.gastro.2017.03.018_bib42","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MEG.0b013e32831101b7","article-title":"Hepatocellular carcinoma after sustained virologic response in hepatitis C patients without cirrhosis on a pretreatment liver biopsy","volume":"21","author":"Sewell","year":"2009","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2017.03.018_bib43","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1365-2893.2008.01006.x","article-title":"Hepatocellular carcinoma in long-term sustained virological responders following antiviral combination therapy for chronic hepatitis C","volume":"15","author":"Scherzer","year":"2008","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1053\/j.gastro.2017.03.018_bib44","doi-asserted-by":"crossref","first-page":"399","DOI":"10.7326\/0003-4819-149-6-200809160-00006","article-title":"Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C","volume":"149","author":"Mallet","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2017.03.018_bib45","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1365-2036.2011.04765.x","article-title":"Liver stiffness diminishes with antiviral response in chronic hepatitis C","volume":"34","author":"Hezode","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2017.03.018_bib46","doi-asserted-by":"crossref","first-page":"e47715","DOI":"10.1371\/journal.pone.0047715","article-title":"Longitudinal liver stiffness assessment in patients with chronic hepatitis C undergoing antiviral therapy","volume":"7","author":"Martinez","year":"2012","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2017.03.018_bib47","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/liv.12628","article-title":"Clinical application of transient elastography in patients with chronic viral hepatitis receiving antiviral treatment","volume":"35","author":"Kim","year":"2015","journal-title":"Liver Int"},{"key":"10.1053\/j.gastro.2017.03.018_bib48","doi-asserted-by":"crossref","first-page":"e0159413","DOI":"10.1371\/journal.pone.0159413","article-title":"Liver stiffness decreases rapidly in response to successful hepatitis C treatment and then plateaus","volume":"11","author":"Chekuri","year":"2016","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2017.03.018_bib49","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/jvh.12578","article-title":"Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy","volume":"23","author":"Knop","year":"2016","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1053\/j.gastro.2017.03.018_bib50","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/apt.13695","article-title":"Liver stiffness measurement using acoustic radiation force impulse elastography in hepatitis C virus-infected patients with a sustained virological response","volume":"44","author":"Tachi","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2017.03.018_bib51","first-page":"59251","article-title":"The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response","author":"D'Ambrosio","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2017.03.018_bib52","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/apt.13722","article-title":"The relationship between liver stiffness measurement and outcome in patients with chronic hepatitis C and cirrhosis: a retrospective longitudinal hospital study","volume":"44","author":"Sultanik","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2017.03.018_bib53","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/liv.13179","article-title":"Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy","volume":"36","author":"Wang","year":"2016","journal-title":"Liver Int"},{"key":"10.1053\/j.gastro.2017.03.018_bib54","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1053\/j.gastro.2016.03.036","article-title":"Effects of eradicating hepatitis C virus infection in patients with cirrhosis differ with stage of portal hypertension","volume":"151","author":"Di Marco","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2017.03.018_bib55","doi-asserted-by":"crossref","first-page":"e0133515","DOI":"10.1371\/journal.pone.0133515","article-title":"Predictive ability of laboratory indices for liver fibrosis in patients with chronic hepatitis C after the eradication of hepatitis C virus","volume":"10","author":"Tachi","year":"2015","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2017.03.018_bib56","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/jgh.12915","article-title":"Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection","volume":"30","author":"Toyoda","year":"2015","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2017.03.018_bib57","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.cgh.2016.01.009","article-title":"Serum biomarkers indicate long-term reduction in liver fibrosis in patients with sustained virological response to treatment for HCV infection","volume":"14","author":"Lu","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2017.03.018_bib58","doi-asserted-by":"crossref","first-page":"e0155967","DOI":"10.1371\/journal.pone.0155967","article-title":"Serological tests do not predict residual fibrosis in hepatitis C cirrhotics with a sustained virological response to interferon","volume":"11","author":"D'Ambrosio","year":"2016","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2017.03.018_bib59","doi-asserted-by":"crossref","unstructured":"Afdhal N, Asselah T, Everson G, et\u00a0al. HCV eradication results in reduction of hepatic venous pressure gradient 48 weeks after end of treatment: final results of the study of sofosbuvir plus ribavirin in patients with cirrhosis and portal hypertension. Late Breaker Poster 518, European Association for the Study of the Liver, Barcelona,\u00a02016.","DOI":"10.1016\/S0168-8278(16)00195-1"},{"key":"10.1053\/j.gastro.2017.03.018_bib60","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","article-title":"Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension","volume":"65","author":"Mandorfer","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2017.03.018_bib61","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.3748\/wjg.v19.i18.2793","article-title":"Sustained virological response: a milestone in the treatment of chronic hepatitis C","volume":"19","author":"Morisco","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.gastro.2017.03.018_bib62","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.cgh.2009.11.018","article-title":"A\u00a0sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus","volume":"8","author":"Singal","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2017.03.018_bib63","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12879-015-0748-8","article-title":"Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits","volume":"15","author":"Smith-Palmer","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1053\/j.gastro.2017.03.018_bib64","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1002\/hep.23528","article-title":"Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study","volume":"51","author":"Bruno","year":"2010","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2017.03.018_bib65","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3851\/IMP1807","article-title":"The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon\/ribavirin therapy","volume":"16","author":"D'Ambrosio","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1053\/j.gastro.2017.03.018_bib66","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2017.03.018_bib67","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/liv.13106","article-title":"Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression?","volume":"36","author":"D'Ambrosio","year":"2016","journal-title":"Liver Int"},{"key":"10.1053\/j.gastro.2017.03.018_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals","author":"Conti","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2017.03.018_bib69","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","volume":"65","author":"Reig","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2017.03.018_bib70","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jhep.2016.05.045","article-title":"Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts","volume":"65","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2017.03.018_bib71","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/apt.13821","article-title":"Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon","volume":"45","author":"Petta","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2017.03.018_bib72","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1365-2893.2008.01010.x","article-title":"Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients","volume":"15","author":"Bruggmann","year":"2008","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1053\/j.gastro.2017.03.018_bib73","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/M16-0816","article-title":"Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial","volume":"165","author":"Dore","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2017.03.018_bib74","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.jhep.2016.01.001","article-title":"Hepatitis C reinfection after sustained virological response","volume":"64","author":"Midgard","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"9","key":"10.1053\/j.gastro.2017.03.018_bib75","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S1473-3099(16)30005-6","article-title":"Access to treatment for hepatitis C virus infection: time to put patients first","volume":"16","author":"Edlin","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1053\/j.gastro.2017.03.018_bib76","doi-asserted-by":"crossref","first-page":"203","DOI":"10.7326\/L15-0485","article-title":"Hepatitis C virus treatment and persons who inject drugs","volume":"164","author":"Grebely","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2017.03.018_bib77","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jhep.2016.08.004","article-title":"Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population","volume":"66","author":"Innes","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2017.03.018_bib78","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jhep.2016.01.034","article-title":"Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population","volume":"64","author":"Bruno","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2017.03.018_bib79","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.24561","article-title":"Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care","volume":"54","author":"Innes","year":"2011","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2017.03.018_bib80","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/cid\/ciu097","article-title":"Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients","volume":"58","author":"Lim","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.gastro.2017.03.018_bib81","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jhep.2016.04.031","article-title":"Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: a prospective study","volume":"65","author":"Vandenbulcke","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2017.03.018_bib82","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jhep.2016.10.017","article-title":"Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication","volume":"66","author":"van der Meer","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2017.03.018_bib83","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/ciw362","article-title":"Diabetes and cirrhosis are risk factors for hepatocellular carcinoma after successful treatment of chronic hepatitis C","volume":"63","author":"Hedenstierna","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.gastro.2017.03.018_bib84","doi-asserted-by":"crossref","first-page":"e4157","DOI":"10.1097\/MD.0000000000004157","article-title":"Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy","volume":"95","author":"Huang","year":"2016","journal-title":"Medicine"},{"key":"10.1053\/j.gastro.2017.03.018_bib85","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1177\/135965350601100401","article-title":"Impact of steatosis on long-term histological outcome in chronic hepatitis C after antiviral therapy","volume":"11","author":"Hung","year":"2006","journal-title":"Antivir Ther"},{"key":"10.1053\/j.gastro.2017.03.018_bib86","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.3748\/wjg.v13.i39.5180","article-title":"Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C","volume":"13","author":"Tanaka","year":"2007","journal-title":"World J Gastroenterol"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001650851730327X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001650851730327X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T15:14:45Z","timestamp":1758035685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001650851730327X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":86,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S001650851730327X"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2017.03.018","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"American Gastroenterological Association Institute Clinical Practice Update\u2014Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2017.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the AGA Institute","name":"copyright","label":"Copyright"}]}}